Business Context and Reporting Period
Company: Outlook Therapeutics, Inc. (OTLK)
Filing Type: Form 8-K (Current Report)
Date of Report: April 22, 2026
Event Date: April 22, 2026 (Offering closed April 23, 2026)
Context: The Company announced a Registered Direct Offering and a concurrent Private Placement to raise capital for working capital and general corporate purposes.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $5.0 million.
- Shares Issued: 16,129,033 shares of Common Stock.
- Offering Price: $0.31 per share (combined price for one share and one Common Warrant).
- Common Warrants Issued: 16,129,033 warrants to purchase Common Stock at an exercise price of $0.31 per share.
- Placement Agent Warrants: 1,129,032 warrants issued to H.C. Wainwright & Co., LLC (7.0% of shares sold) with an exercise price of $0.3875 per share.
- Transaction Fees: 7.0% cash fee and 1.0% management fee payable to the Placement Agent.
- Use of Proceeds: Working capital and general corporate purposes.
Material Changes and Warrant Amendments
In connection with the Offering, the Company amended outstanding warrants previously issued in January 2025:
- Warrants Amended: 2,142,854 shares of Common Stock.
- Previous Exercise Price: $2.26 per share.
- New Exercise Price: Reduced to $0.31 per share.
- Exercisability: Effective upon stockholder approval of the issuance of shares underlying the Amended Warrants.
- Expiration: Five years from the effective date of stockholder approval.
Guidance, Outlook, and Risks
- Stockholder Approval Required: The Company must hold a stockholder meeting within 90 days of the Offering closing to approve the issuance of Common Warrant Shares and an increase in authorized shares.
- Warrant Exercisability: Common Warrants and Amended Warrants are not exercisable until the later of stockholder approval or the effective date of the charter amendment increasing authorized shares.
- Registration Rights: The Company agreed to file a Resale Registration Statement on Form S-3 within five calendar days of the effective date of the Increase of Authorized Shares.
- Forward-Looking Risks: Actual results may differ due to risks related to closing conditions, stockholder approval, and general market uncertainties as detailed in the Company's Form 10-K for the year ended September 30, 2025.
Investor Verification Checklist
- Verify the outcome of the stockholder meeting required within 90 days to approve the warrant shares and authorized share increase.
- Confirm the effective date of the Resale Registration Statement (Form S-3) for the Common Warrant Shares.
- Monitor the Company's cash burn rate and runway given the $5.0 million gross proceeds raised.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and termination provisions.
- Check for any subsequent filings regarding the exercise of the Amended Warrants or the new Common Warrants.